Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2025. The report discloses the granting of Deferred Annual Bonus Plan (DABP) awards to Persons Discharging Managerial Responsibilities (PDMRs) on February 17, 2025. These awards are granted in accordance with the GlaxoSmithKline 2017 Deferred Annual Bonus Plan, requiring executives to defer portions of their bonuses into Ordinary Shares or American Depositary Shares (ADS) for a three-year period.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a transaction notification regarding executive compensation.
Transaction details for the awards granted on February 17, 2025, include:
- Instrument: Ordinary Shares (31 1/4 pence each) and American Depositary Shares (ADS).
- Valuation Price: Ordinary Shares were valued at £14.35; ADS were valued at $36.17.
- Total Volume: The filing lists individual share/ADS counts for 12 executives, totaling 366,505 Ordinary Shares and 11,288 ADS.
Material Changes
The filing does not contain comparative financial data or material changes to the company's operational performance versus prior periods. The only reported activity is the initial notification of bonus awards for the current period.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose new risks or contingencies beyond the standard terms of the Deferred Annual Bonus Plan, which includes a three-year deferral period and dividend reinvestment accruals.
Investor Verification Checklist
- Verify the total number of shares and ADS granted to PDMRs against the company's latest proxy statement or remuneration report.
- Confirm the share price of £14.35 and ADS price of $36.17 used for the valuation of these awards.
- Review the specific deferral percentages (50% for Executive Directors, 25% for other Leadership Team members) to ensure compliance with the 2022 Remuneration Policy.
- Note that the reported volumes exclude dividend reinvestment that will accrue during the deferral period.